Efficacy and safety of brigatinib (AP26113) in ALK+ NSCLC: phase 1/2 trial results

被引：0

作者：

Gettinger, S. N. ^{[1
]}

Bazhenova, L. A. ^{[2
]}

Salgia, R. ^{[3
]}

Langer, C. J. ^{[4
]}

Gold, K. ^{[5
]}

Rosell, R. ^{[6
]}

Shaw, A. T. ^{[7
]}

Weiss, G. J. ^{[8
]}

Dorer, D. J. ^{[9
]}

Rivera, V. M. ^{[10
]}

Kerstein, D. ^{[11
]}

Camidge, D. R. ^{[12
]}

机构：

[1] Yale Canc Ctr, Med Oncol, New Haven, CT USA

[2] Univ Calif San Diego, Moores Canc Ctr, Med Oncol, La Jolla, CA 92093 USA

[3] Univ Chicago Med, Biomed Sci, Chicago, IL USA

[4] Univ Penn, Abramson Canc Ctr, Thorac Oncol, Philadelphia, PA 19104 USA

[5] Univ Texas MD Anderson Canc Ctr, Thorac Head & Neck Med Oncol, Houston, TX 77030 USA

[6] Catalan Inst Oncol, Med Oncol, Barcelona, Spain

[7] Massachusetts Gen Hosp, Dept Med, Ctr Canc, Boston, MA 02114 USA

[8] Canc Treatment Ctr Amer, Western Reg Med Ctr, Goodyear, AZ USA

[9] ARIAD Pharmaceut Inc, Biostat, Cambridge, MA 02139 USA

[10] ARIAD Pharmaceut Inc, Preclin & Translat Res, Cambridge, MA 02139 USA

[11] ARIAD Pharmaceut Inc, Clin Res, Cambridge, MA 02139 USA

[12] Univ Colorado, Ctr Canc, Med Oncol, Aurora, CO USA

来源：

LUNG CANCER | 2016年 / 91卷

关键词：

D O I：

10.1016/S0169-5002(16)30073-3

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S20 / S21

页数：2

共 50 条

[31] Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial
Camidge, D. Ross
Kim, Hye Ryun
Ahn, Myung-Ju
Yang, James C. H.
Han, Ji-Youn
Hochmair, Maximilian J.
Lee, Ki Hyeong
Delmonte, Angelo
Campelo, Maria Rosario Garcia
Kim, Dong-Wan
Griesinger, Frank
Felip, Enriqueta
Califano, Raffaele
Spira, Alexander I.
Gettinger, Scott N.
Tiseo, Marcello
Lin, Huamao M.
Liu, Yuyin
Vranceanu, Florin
Niu, Huifeng
Zhang, Pingkuan
Popat, Sanjay
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (12) : 2091 - 2108
[32] Brigatinib vs crizotinib in patients with ALK inhibitor-naive advanced ALK1 NSCLC: Updated results from the phase III ALTA-1L trial
Camidge, R.
Kim, H. R.
Ahn, M-J.
Yang, J. C-H.
Han, J-Y.
Hochmair, M. J.
Lee, K. H.
Delmonte, A.
Garcia Campelo, M. R.
Kim, D-W.
Griesinger, F.
Felip, E.
Califano, R.
Spira, A.
Gettinger, S.
Tiseo, M.
Ni, Q.
Zhang, P.
Popat, S.
ANNALS OF ONCOLOGY, 2019, 30
[33] AP26113 possesses pan-inhibitory activity versus crizotinib-resistant ALK mutants and oncogenic ROS1 fusions.
Squillace, Rachel M.
Anjum, Rana
Miller, David
Vodala, Sadanand
Moran, Lauren
Wang, Frank
Clackson, Tim
Garner, Andrew P.
Rivera, Victor M.
CANCER RESEARCH, 2013, 73 (08)
[34] Iruplinalkib in Patients with ALK-Positive CrizotinibResistant NSCLC: Updated Efficacy and Safety Data from a Phase 2 Trial
Shi, Y.
Chen, J.
Zhang, H.
Zhang, Z.
Zhang, Y.
Wang, Z.
Zhang, S.
Zhao, J.
Liu, C.
Wang, X.
Zhao, Y.
Hu, C.
Yang, L.
Hao, X.
Wang, L.
Liu, Y.
Yu, Y.
Zhao, J.
Wang, M.
Zhang, L.
Sun, S.
Hu, Y.
Gu, K.
Hang, X.
Shan, J.
Zhang, Y.
Tan, B.
Yang, W.
Yang, R.
Si, M.
Li, H.
Kang, X.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S203 - S203
[35] Brigatinib vs Crizotinib in patients (pts) with ALK inhibitornaive advanced ALK plus NSCLC from the phase 3 ALTA-1L trial
Griesinger, F.
Camidge, D. R.
Kim, H. R.
Ahn, M. -J.
Yang, J. C. -H.
Han, J. -Y.
Lee, J. -S.
Hochmair, M.
Li, J. Y. -C.
Chang, G. -C.
Lee, K. H.
Gridelli, C.
Delmonte, A.
Campelo, Garcia M. R.
Kim, D. -W.
Bearz, A.
Morabito, A.
Felip, E.
Califano, R.
Ghosh, S.
Spira, A.
Gettinger, S.
Tiseo, M.
Haney, J.
Kerstein, D.
Popat, S.
ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 75 - 76
[36] Updated Results from the Phase 3 ALTA-1L Trial of Brigatinib (BRG) vs. Crizotinib (CRZ) in ALK Inhibitor-Naive Advanced ALK plus NSCLC
Griesinger, Frank
Camidge, D. Ross
Kim, Hye Ryun
Ahn, Myung-Ju
Yang, James Chih-Hsin
Han, Ji Youn
Hochmair, Maximilian
Lee, Hyeong
Delmonte, Angelo
Garcia Compelo, Maria Rosario
Kim, Dong-Wan
Felip, Enriqueta
Califano, Raffaele
Spire, Alexander
Gettinger, Scott N.
Tiseo, Marcello
Lin, Huamao M.
Ni, Quanhong
Zhang, Pingkuan
Popat, Sanjay
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 232 - 232
[37] Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial
Yang, James Chih-Hsin
Liu, Geoffrey
Lu, Shun
He, Jianxing
Burotto, Mauricio
Ahn, Myung-Ju
Kim, Dong-Wan
Liu, Xiaoqing
Zhao, Yanqiu
Vincent, Sylvie
Yin, Jiani
Ma, Xin
Lin, Huamao M.
Popat, Sanjay
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (12) : 1743 - 1755
[38] Integrated efficacy and safety of brigatinib in patients with ALK TKI-naive advanced ALK plus NSCLC in the ALTA-1L and J-ALTA studies
Camidge, D. Ross
Sugawara, Shunichi
Kondo, Masashi
Kim, Hye Ryun
Ahn, Myung-Ju
Yang, James Chih-Hsin
Han, Ji-Youn
Hochmair, Maximilian J.
Lee, Ki Hyeong
Delmonte, Angelo
Kudou, Kentarou
Asato, Takayuki
Liu, Yuyin
Vranceanu, Florin
Fram, Robert J.
Ohe, Yuichiro
Popat, Sanjay
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[39] Brigatinib (BRG) in patients (pts) with ALK plus non-small cell lung cancer (NSCLC): Updates from a phase 1/2 trial.
Bazhenova, Lyudmila
Gettinger, Scott N.
Langer, Corey J.
Salgia, Ravi
Gold, Kathryn A.
Rosell, Rafael
Shaw, Alice Tsang
Weiss, Glen J.
Haney, Jeff
Rivera, Victor M.
Kerstein, David
Camidge, D. Ross
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[40] Brigatinib in Crizotinib-Refractory ALK plus NSCLC: Central Assessment and Updates from ALTA, a Pivotal Randomized Phase 2 Trial
Camidge, D. Ross
Tiseo, Marcello
Ahn, Myung-Ju
Reckamp, Karen
Hansen, Karin
Kim, Sang-We
Huber, Rudolf
West, Howard
Groen, Harry
Hochmair, Maximilian
Leighl, Natasha
Gettinger, Scott
Langer, Corey
Paz-Ares, Luis
Smit, Egbert
Kim, Edward
Reichmann, William
Clackson, Tim
Kerstein, David
Haluska, Frank
Kim, Dong-Wan
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1167 - S1169

← 1 2 3 4 5 →